Page 106 - 《中国药房》2026年9期
P. 106

急性髓系白血病患者维奈托克血浆谷浓度的影响因素及其与

          疗效的关系研究                   Δ



                                            3
                                                     1 #
          何韦韦    1, 2* ,刘职瑞 ,秦士玮 ,宫 蔷 ,程 林 (1.陆军军医大学第一附属医院药剂科,重庆 400038;2.陆军
                                    1
                            1
          军医大学第一附属医院感染病科,重庆 400038;3.陆军军医大学第一附属医院血液科,重庆 400038)
          中图分类号  R733;R969      文献标志码  A      文章编号  1001-0408(2026)09-1200-06
          DOI  10.6039/j.issn.1001-0408.2026.09.16

          摘   要  目的  探讨急性髓系白血病(AML)患者维奈托克血浆谷浓度、疗效及其影响因素之间的关系。方法  AML患者服用维奈
          托克5 d后,于下次给药前采集静脉血,采用高效液相色谱-串联质谱法测定维奈托克血浆谷浓度。采用Spearman相关性分析评估
          维奈托克血浆谷浓度与各指标(包括患者一般资料、维奈托克相关指标、肝功能指标、肾功能指标、血常规指标等)之间的相关性,
          采用多元线性回归分析维奈托克血浆谷浓度的独立影响因素;以疗效为因变量[完全缓解(CR)+部分缓解(PR)vs.未缓解(NR)],
          采用单因素和多因素二元Logistic回归分析影响疗效的因素。采用受试者工作特征(ROC)曲线评估维奈托克血浆谷浓度对临床
          疗效(以CR计)的预测价值。结果  本研究共纳入101例患者的172个维奈托克血浆谷浓度检测值。维奈托克中位血浆谷浓度为
          2.38(1.18,3.85)μg/mL;维奈托克血浆谷浓度中位检测时间为10(7,15)d;维奈托克使用天数为(34±12)d。多元线性回归分析结
          果显示,碱性磷酸酶(B=14.65,95%CI 为 5.35~23.95,P=0.002)、总胆红素(B=-101.71,95%CI 为-197.16~-6.25,P=0.037)
          和白细胞计数(B=-106.84,95%CI 为-187.61~-26.07,P=0.010)是维奈托克血浆谷浓度的独立影响因素。因治疗过程中有
          患者脱落,共纳入69例患者的114个维奈托克血浆谷浓度进行疗效评估,结果显示,CR、PR、NR患者分别有46例(66.7%)、11例
         (15.9%)和12例(17.4%)。多因素二元Logistic回归分析结果显示,年龄、血红蛋白、维奈托克血浆谷浓度、红细胞压积、平均血红
          蛋白含量是患者疗效的独立影响因素(P<0.05);ROC曲线分析结果显示,预测患者疗效(以CR计)的维奈托克血浆谷浓度截断
          值为1.68 μg/mL(AUC=0.66,95%CI为0.54~0.78,P=0.014)。结论  维奈托克血浆谷浓度在AML患者中存在较大的个体差异,
          与碱性磷酸酶、总胆红素、白细胞计数存在显著相关性;维奈托克血浆谷浓度是患者疗效的独立影响因素,血浆谷浓度在 1.68
          μg/mL以上时可能获得更好的治疗效果。
          关键词  维奈托克;急性髓系白血病;血药浓度;谷浓度;临床疗效;影响因素

          Study  on  the  influencing  factors  of  venetoclax  trough  concentration  and  its  association  with  efficacy  in
          patients with acute myeloid leukemia
                                 1
                                                                       1
                    1, 2
          HE Weiwei ,LIU Zhirui ,QIN Shiwei ,GONG Qiang ,CHENG Lin(1. Dept. of Pharmacy, the First Affiliated
                                             1
                                                          3
          Hospital  of  Army  Medical  University,  Chongqing  400038,  China;2.  Dept.  of  Infectious  Diseases,  the  First
          Affiliated  Hospital  of Army  Medical  University,  Chongqing  400038,  China;3.  Dept.  of  Hematology,  the  First
          Affiliated Hospital of Army Medical University, Chongqing 400038, China)
          ABSTRACT    OBJECTIVE  To  investigate  the  effect  of  plasma  trough  concentration  of  venetoclax  and  its  influencing  factors  in
          patients  with  acute  myeloid  leukemia (AML).  METHODS  After  5  days  of  venetoclax  administration,  venous  blood  samples  were
          collected  from  AML  patients  before  the  next  dose.  Plasma  trough  concentrations  of  venetoclax  were  determined  using  high-
          performance  liquid  chromatography-tandem  mass  spectrometry.  Spearman  correlation  was  used  to  assess  the  correlations  between
          venetoclax  plasma  trough  concentration  and  various  parameters (including  patients’  general  information,  venetoclax-related
          indicators,  liver  function  indicators,  kidney  function  indicators,  and  blood  routine  indicators).  Multiple  linear  regression  analysis
          was  performed  to  identify  independent  factors  influencing  plasma  trough  concentration  of  venetoclax.  Using  efficacy  as  dependent
                                                              variable  [complete  remission (CR)+partial  remission (PR)  vs.
              Δ 基金项目 重庆市科卫联合医学科研面上项目(No.2024MSXM-
          028);重庆市沙坪坝区科卫联合医学科研面上项目(No.2025SQKW-               no  remission  (NR)],  univariate  and  multivariate  binary
          LHMS023);重庆市临床药学重点专科(No.渝卫办发〔2021〕52号)              Logistic  regression  analyses  were  conducted  to  identify  factors
             *第一作者 主管技师。研究方向:临床生物化学检验诊断技术。
                                                              affecting  efficacy.  The  receiver  operating  characteristic (ROC)
          E-mail:hww19890706@163.com
                                                              curve  was  used  to  evaluate  the  predictive  value  of  venetoclax
              # 通信作者 副主任药师,硕士。研究方向:治疗药物监测。电话:
          023-68766797。E-mail:chenglin@tmmu.edu.cn            plasma  trough  concentration  for  clinical  efficacy (assessed  as


          · 1200 ·    China Pharmacy  2026 Vol. 37  No. 9                              中国药房  2026年第37卷第9期
   101   102   103   104   105   106   107   108   109   110   111